COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04662086|
Recruitment Status : Not yet recruiting
First Posted : December 10, 2020
Last Update Posted : February 8, 2021
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization. The overall hypothesis is that through an adaptive trial design, potential effective therapies (single and combination) may be identified for this group of patients.
COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the platform, every investigational product will collect data for both Domain primary endpoints. Individual treatments to be evaluated in the platform will be described in separate sub-protocols.
|Condition or disease||Intervention/treatment||Phase|
|Covid19||Drug: Acebilustat Drug: Camostat||Phase 2|
The platform study allows investigational products with objectives either: evaluating viral shedding (Virology Domain); and COVID-19 related Clinical Outcomes (Clinical Domain).
The primary objective for investigational products within the Viral Domain is:
A. To evaluate the efficacy of each therapeutic intervention in addition to standard supportive care (SSC) compared with SSC in reducing the duration of viral shedding of SARS-CoV-2 virus in outpatients with COVID-19 disease.
The primary objective for investigational products within for the Clinical Domain is:
B. To evaluate the efficacy of each therapeutic intervention in addition to SSC as compared to SSC in improving sustained clinical outcomes in outpatients with COVID-19 disease.
Secondary objectives are:
The objective of the non-assigned domain an investigational product is under.
- If under Clinical Domain, time to cessation of viral shedding.
- If under Viral Domain, time to sustained resolution of symptoms.
- To evaluate the efficacy of each therapeutic intervention in reducing SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.
- To assess the development of antibodies against SARS-CoV-2
- To evaluate the safety and tolerability of each therapeutic intervention compared with placebo (supportive care).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||240 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19|
|Estimated Study Start Date :||March 2021|
|Estimated Primary Completion Date :||March 2022|
|Estimated Study Completion Date :||March 2022|
Participants are randomized to receive either active acebilustat or matching placebo.
100-mg capsule administered orally once daily
Participants are randomized to receive either active camostat or matching placebo.
200-mg tablet administered orally four times daily
- For Viral Domain:Time until cessation of shedding of SARS-CoV-2 virus [ Time Frame: 28 days ]Defined as the time in days from randomization to the first of two consecutive negative RT-PCR results of self-collected nasal swabs
- For Clinical Domain: Time from randomization to sustained symptom resolution assessed over a 28-day period [ Time Frame: 28 days ]Resolution is defined as the first study day where no symptoms are self-reported for 48 hours, not including sense of taste or smell, and defining recovery for fatigue and cough as mild or none. Participants who never experienced resolution will be censored at their last survey completion day.
- Time to first resolution [ Time Frame: 28 days ]Defined as the first study day where no symptoms are self-reported, not including sense of taste or smell, and defining recovery for fatigue and cough as mild or none.
- Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease. [ Time Frame: 28 days ]
- Indicator participant has developed antibodies to SARS-CoV-2 [ Time Frame: 28 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04662086
|United States, California|
|Stanford, California, United States, 94305|
|Principal Investigator:||Manisha Desai, PhD||Stanford University|
|Principal Investigator:||Upinder Singh, MD||Stanford University|
|Principal Investigator:||Yvonne Maldonado, MD||Stanford University|
|Principal Investigator:||Chaitan Khosla, PhD||Stanford University|
|Principal Investigator:||Haley Hedlin, PhD||Stanford University|